Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|July 2, 2022
- Pharmaceutical Technology, July 2022
- Volume 46
- Issue 7
- Pages: 12
Aseptic Tubing Connector
Author(s)Pharmaceutical Technology Editors
The AseptiQuik G DC connector is a single, sterile connection technology that can connect and disconnect tubing aseptically.
Colder Products Company’s AseptiQuik G DC Series Connector is designed to connect and disconnect tubing aseptically through a single, sterile connection. The latest in the company’s AseptiQuik G line of genderless sterile connectors, the product can make quick sterile connections and disconnections in both sterile and non-sterile environments without requiring any ancillary equipment.
The AseptiQuik G DC connector’s “FLIP-CLICK-PULL” assembly is designed to help users transfer liquids easily. After transfer is complete, a simple two-step disconnection process maintains system sterility. AseptiQuik G DC connector hose barb termination sizes include quarter inch, three-eighth inch, and half-inch sizes.
Articles in this issue
over 4 years ago
Getting Proactive with Pharma Packagingover 4 years ago
Advancing Accessibility through Point-of-Use Manufacturingover 4 years ago
Formulating Biologics: A Learning Curveover 4 years ago
Automating Biopharma Manufacturingover 4 years ago
Challenges to Formulation Development for Highly Potent APIsover 4 years ago
Prefilled Syringes Show Strong Growthover 4 years ago
Trends in International Arbitration: The Fallout from COVID-19Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.